Počet záznamov: 1
trastuzumab
SYS d000068878 LBL 00000cz--a2200181n--4500 005 20250606221740.3 008 160101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 $d BA006 $d BA006 $d BA006 065 $a D12.776.124.486.485.114.224.060.875 065 $a D12.776.124.790.651.114.224.060.875 065 $a D12.776.377.715.548.114.224.200.875 066 $a 01 $c 03 150 $a trastuzumab $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo 450 $w v $a Trastuzumab beta $2 eng 450 $w v $a Trastuzumab-qyyp $2 eng 450 $w v $a Trazimera $2 eng 450 $w v $a trastuzumab-qyyp $2 slo 450 $w v $a Trastuzumab beta $2 slo 450 $w v $a Trazimera $2 slo 450 $w v $a Herceptin $2 slo 550 $7 sllk_us_auth*d018719 $Y Receptor, ErbB-2 $w b $a receptor erbB-2 550 $7 sllk_us_auth*d000074322 $Y Antineoplastic Agents, Immunological $w P $a antineoplastiká imunologické 550 $7 sllk_us_auth*d018719 $Y Receptor, ErbB-2 $w p $a receptor erbB-2 665 $a 2016 (1998) $2 eng 680 9-
$i A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed. $2 eng 750 -2
$a Trastuzumab $2 eng 980 $x M
Počet záznamov: 1